ACELYRIN, INC. Common Stock Market Cap ($229.17 Million)
Market Cap & Net Worth: ACELYRIN, INC. Common Stock (SLRN)
ACELYRIN, INC. Common Stock market cap. ACELYRIN, INC. Common Stock (NASDAQ:SLRN) has a market capitalization of $229.17 Million ($229.17 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15812 globally and #3775 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ACELYRIN, INC. Common Stock's stock price $2.27 by its total outstanding shares 100954000 (100.95 Million). Also see ACELYRIN, INC. Common Stock (SLRN) cash flow conversion for how efficiently the company converts equity into cash flow.
ACELYRIN, INC. Common Stock Market Cap History (2023–2025)
ACELYRIN, INC. Common Stock market cap history from 2023 to 2025. Data shows change from $753.12 Million to $229.17 Million (-63.54% CAGR). Check SLRN stock price for real-time trading data and today's change.
Index Memberships
ACELYRIN, INC. Common Stock is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.01% | #423 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1547 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.01% | #215 of 263 |
Weight: ACELYRIN, INC. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ACELYRIN, INC. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ACELYRIN, INC. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore SLRN net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of SLRN by Market Capitalization
Companies near ACELYRIN, INC. Common Stock in the global market cap rankings as of November 4, 2026. Also see ACELYRIN, INC. Common Stock asset portfolio for a full breakdown of the balance sheet.
Key companies related to ACELYRIN, INC. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of ACELYRIN, INC. Common Stock (2023–2025)
Market capitalization of ACELYRIN, INC. Common Stock from 2023 to today. Between 2023 and today, ACELYRIN, INC. Common Stock's market cap moved from $753.12 Million to $ 229.17 Million, with a yearly change of -63.54%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $229.17 Million | -27.71% |
| 2024 | $317.00 Million | -57.91% |
| 2023 | $753.12 Million | -- |
End of Day Market Cap According to Different Sources
On May 21st, 2026 the market cap of ACELYRIN, INC. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $229.17 Million USD |
| MoneyControl | $229.17 Million USD |
| MarketWatch | $229.17 Million USD |
| marketcap.company | $229.17 Million USD |
| Reuters | $229.17 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ACELYRIN, INC. Common Stock
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED). Acelyrin, Inc. was incorp… Read more